JMP maintains Gilead at market perform

Gilead Sciences Inc. was maintained by JMP Securities LLC analyst Adam Cutler at a market perform rating after Gilead reported third-quarter earnings per share of $0.38, above JMP estimates of $0.34 a share and consensus of $0.37 a share. JMP said it was impressed with Gilead's execution and growth, but there is doubt about how much more growth the company can squeeze out of its HIV franchise. Shares of the Foster City, Calif.-based biopharmaceutical company were down $2.22, or 4.60%, at $46.01 on volume of 11,686,195 shares versus the three-month running average of 3,636,390 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.